The results obtained in advanced malignant lymphomas with three new drug combinations including adriamycin are reported in this paper. In patients with Hodgkin's disease, the quadruple combination of adriamycin, bleomycin, vinblastine and NSV 45388 (ABVD) in a controlled trial produced a percent of complete remission and a median duration of response comparable to those obtained with mechlorethamine, vincristine, (oncovin) prednisone and procarbazine (MOPP). Similar results were observed in the group of patients with nonHodgkin's lymphomas where adriamycin, bleomycin, and prednisone (ABP) were randomly tested against cyclophosphamide, vincristine, and prednisone (CVP). Initial evidence shows a lack of cross resistance between ABVD and MOPP as well as between ABP and CVP. These data favor the design of new combinations and new approaches for the best management of patients with advanced malignant lymphomas. Combinations that include adriamycin and bleomycin may, however, produce severe toxicity (cardiomyopathy, lung fibrosis) when these drugs are used as longterm therapy.
|Title of host publication||CANCER CHEMOTHER.REP.|
|Number of pages||8|
|Publication status||Published - 1975|
ASJC Scopus subject areas